Home / Articles / Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering

Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering

Sergei Mikhailovich Deyev 1
Sergei Mikhailovich Deyev
, 
Ekaterina Nikolaevna Lebedenko 1
Ekaterina Nikolaevna Lebedenko
, 
Lada Evgen'evna Petrovskaya 1
Lada Evgen'evna Petrovskaya
, 
Dmitry Aleksandrovich Dolgikh 1
Dmitry Aleksandrovich Dolgikh
, 
Aleksandr Gabibovich Gabibov 1
Aleksandr Gabibovich Gabibov
, 
M P Kirpichnikov 1
M P Kirpichnikov
1 M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow
10.1070/RCR4459
Published 30 November 2014
Communication , Volume 84, Issue 1, 1-26
57
Share
Cite this
GOST
 | 
Cite this
GOST
Copy cite
Deyev S. M. et al. Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering // Russian Chemical Reviews. 2015. Vol. 84. No. 1. pp. 1-26.
GOST all authors (up to 50)
Copy cite
Deyev S. M., Lebedenko E. N., Petrovskaya L. E., Dolgikh D. A., Gabibov A. G., Kirpichnikov M. P. Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering // Russian Chemical Reviews. 2015. Vol. 84. No. 1. pp. 1-26.
RIS
 | 
Cite this
RIS
Copy cite
TY - JOUR
DO - 10.1070/RCR4459
UR - https://rcr.colab.ws/publications/10.1070/RCR4459
TI - Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering
T2 - Russian Chemical Reviews
AU - Deyev, Sergei Mikhailovich
AU - Lebedenko, Ekaterina Nikolaevna
AU - Petrovskaya, Lada Evgen'evna
AU - Dolgikh, Dmitry Aleksandrovich
AU - Gabibov, Aleksandr Gabibovich
AU - Kirpichnikov, M P
PY - 2015
DA - 2014/11/30
PB - ANO Editorial Board of the journal Uspekhi Khimii
SP - 1-26
IS - 1
VL - 84
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors)
Copy cite
@article{2015_Deyev,
author = {Sergei Mikhailovich Deyev and Ekaterina Nikolaevna Lebedenko and Lada Evgen'evna Petrovskaya and Dmitry Aleksandrovich Dolgikh and Aleksandr Gabibovich Gabibov and M P Kirpichnikov},
title = {Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering},
journal = {Russian Chemical Reviews},
year = {2015},
volume = {84},
publisher = {ANO Editorial Board of the journal Uspekhi Khimii},
month = {Nov},
url = {https://rcr.colab.ws/publications/10.1070/RCR4459},
number = {1},
pages = {1--26},
doi = {10.1070/RCR4459}
}
MLA
Cite this
MLA
Copy cite
Deyev, Sergei Mikhailovich, et al. “Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering.” Russian Chemical Reviews, vol. 84, no. 1, Nov. 2015, pp. 1-26. https://rcr.colab.ws/publications/10.1070/RCR4459.
Views / Visits / Downloads
45 / 45 / 12

Abstract

The review outlines progress and problems in the design of non-natural antibodies for clinical applications over the past 10--15 years. The modular structure of natural antibodies and approaches to its targeted modifications and combination with other structural elements and effector molecules are considered. The review covers modern methods for immunoglobulin engineering and promising strategies for the creation and applications of monoclonal antibodies, their derivatives and analogues, including abzymes and scaffolds, oriented to the use in the diagnosis and targeted therapy of cancer and other socially significant diseases.

The bibliography includes 225 references.

References

2.
ERBB oncogene proteins as targets for monoclonal antibodies
Polanovski O.L., Lebedenko E.N., Deyev S.M.
Biochemistry (Moscow) , 2012
4.
5
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1953
5.
6
V. B. Evstigneev
Dokl. Akad. Nauk SSSR , 1953
7.
Monoclonal antibodies based on hybridoma technology
Yagami H., Kato H., Tsumoto K., Tomita M.
Pharmaceutical patent analyst , 2013
8.
Chemically programmed antibodies
Rader C.
Trends in Biotechnology , 2014
9.
Emerging Principles for the Therapeutic Exploitation of Glycosylation
Dalziel M., Crispin M., Scanlan C.N., Zitzmann N., Dwek R.A.
Science , 2014
11.
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner L.M., Surana R., Wang S.
Nature Reviews Immunology , 2010
12.
Recombinant antibodies for cancer therapy
Deonarain M.P.
Expert Opinion on Biological Therapy , 2008
14.
Potent antibody therapeutics by design
Carter P.J.
Nature Reviews Immunology , 2006
16.
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang X., Song A., Bergelson S., Arroll T., Parekh B., May K., Chung S., Strouse R., Mire-Sluis A., Schenerman M.
Nature Reviews Drug Discovery , 2011
18.
Generation of recombinant antibodies and means for increasing their affinity
Altshuler E.P., Serebryanaya D.V., Katrukha A.G.
Biochemistry (Moscow) , 2010
19.
20
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1954
20.
Arming antibodies: prospects and challenges for immunoconjugates
Wu A.M., Senter P.D.
Nature Biotechnology , 2005
22.
Chemical generation of bispecific antibodies
Doppalapudi V.R., Huang J., Liu D., Jin P., Liu B., Li L., Desharnais J., Hagen C., Levin N.J., Shields M.J., Parish M., Murphy R.E., Del Rosario J., Oates B.D., Lai J., et. al.
Proceedings of the National Academy of Sciences of the United States of America , 2010
23.
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
Schaefer G., Haber L., Crocker L., Shia S., Shao L., Dowbenko D., Totpal K., Wong A., Lee C., Stawicki S., Clark R., Fields C., Lewis Phillips G., Prell R., Danilenko D., et. al.
Cancer Cell , 2011
24.
Using antibodies to target cancer therapeutics
Goldenberg D.M., Sharkey R.M.
Expert Opinion on Biological Therapy , 2012
25.
Site-specific antibody drug conjugates for cancer therapy
Panowski S., Bhakta S., Raab H., Polakis P., Junutula J.R.
mAbs , 2013
27.
The safety and side effects of monoclonal antibodies
Hansel T.T., Kropshofer H., Singer T., Mitchell J.A., George A.J.
Nature Reviews Drug Discovery , 2010
28.
Antibody-Based Immunotherapy of Cancer
Weiner L., Murray J., Shuptrine C.
Cell , 2012
31.
Goldenberg D.M., Chang C., Rossi E.A., McBride W.J., Sharkey R.M.
Theranostics , 2012
32.
33
M. B. Neiman
"Issledovanie Mekhanizma Okisleniya Butana" (Research on the Mechanism of the Oxidation of Butane) , 1939
34.
Single-chain antigen-binding proteins.
Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S., Lee T., Pope S.H., Riordan G.S., Whitlow M.
Science , 1988
35.
Design of synthetic antibody libraries
Benhar I.
Expert Opinion on Biological Therapy , 2007
36.
Method for generation of human hyperdiversified antibody fragment library
Mondon P., Souyris N., Douchy L., Crozet F., Bouayadi K., Kharrat H.
Biotechnology Journal , 2007
37.
Selecting and screening recombinant antibody libraries
Hoogenboom H.R.
Nature Biotechnology , 2005
38.
Selection of antibodies from synthetic antibody libraries
Harel Inbar N., Benhar I.
Archives of Biochemistry and Biophysics , 2012
39.
Naturally occurring antibodies devoid of light chains
Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hammers C., Songa E.B., Bendahman N., Hammers R.
Nature , 1993
40.
A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks
Greenberg A.S., Avila D., Hughes M., Hughes A., McKinney E.C., Flajnik M.F.
Nature , 1995
41.
Immunogenicity screening in protein drug development
Van Walle I., Gansemans Y., Parren P.W., Stas P., Lasters I.
Expert Opinion on Biological Therapy , 2007
42.
T cell epitope: Friend or Foe? Immunogenicity of biologics in context☆
Weber C.A., Mehta P.J., Ardito M., Moise L., Martin B., De Groot A.S.
Advanced Drug Delivery Reviews , 2009
44.
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T.
Proceedings of the National Academy of Sciences of the United States of America , 1984
45.
Production of recombinant antibodies in lymphoid and non-lymphoid cells
Deyev S.M., Lieber A., Radko B.V., Polanovsky O.L.
FEBS Letters , 1993
46.
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G.
Nature , 1986
47.
Expression of humanized anti-Her2/neu single-chain IgG1-like antibody in mammary glands of transgenic mice
Yuskevich V., Khodarovich Y., Kagarliskiy G., Stremovskiy O., Maksimenko O., Lukash S., Polanovsky O., Deyev S.
Biochimie , 2011
48.
Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions
Bernett M.J., Karki S., Moore G.L., Leung I.W., Chen H., Pong E., Nguyen D.T., Jacinto J., Zalevsky J., Muchhal U.S., Desjarlais J.R., Lazar G.A.
Journal of Molecular Biology , 2010
50.
51
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1954
51.
SDR grafting—a new approach to antibody humanization
Kashmiri S.V., De Pascalis R., Gonzales N.R., Schlom J.
Methods , 2005
52.
Humanization of murine monoclonal antibodies through variable domain resurfacing.
Roguska M.A., Pedersen J.T., Keddy C.A., Henry A.H., Searle S.J., Lambert J.M., Goldmacher V.S., Blättler W.A., Rees A.R., Guild B.C.
Proceedings of the National Academy of Sciences of the United States of America , 1994
53.
A molecular immunology approach to antibody humanization and functional optimization
Lazar G.A., Desjarlais J.R., Jacinto J., Karki S., Hammond P.W.
Molecular Immunology , 2007
55.
General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold
Vincke C., Loris R., Saerens D., Martinez-Rodriguez S., Muyldermans S., Conrath K.
Journal of Biological Chemistry , 2009
56.
Antibody constructs in cancer therapy
Beckman R.A., Weiner L.M., Davis H.M.
Cancer , 2007
57.
Kinetic and affinity limits on antibodies produced during immune responses.
Foote J., Eisen H.N.
Proceedings of the National Academy of Sciences of the United States of America , 1995
59.
61
A. N. Terenin
1959
60.
Interaction between Shiga Toxin and Monoclonal Antibodies: Binding Characteristics and in Vitro Neutralizing Abilities
Rocha L.B., Luz D.E., Moraes C.T., Caravelli A., Fernandes I., Guth B.E., Horton D.S., Piazza R.M.
Toxins , 2012
61.
Engineering the variable region of therapeutic IgG antibodies
Igawa T., Tsunoda H., Kuramochi T., Sampei Z., Ishii S., Hattori K.
mAbs , 2011
62.
Affinity maturation of antibodies assisted by in silico modeling
Barderas R., Desmet J., Timmerman P., Meloen R., Casal J.I.
Proceedings of the National Academy of Sciences of the United States of America , 2008
63.
Computer-aided antibody design
Kuroda D., Shirai H., Jacobson M.P., Nakamura H.
Protein Engineering, Design and Selection , 2012
64.
Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design
Clark L.A., Boriack-Sjodin P.A., Eldredge J., Fitch C., Friedman B., Hanf K.J., Jarpe M., Liparoto S.F., Li Y., Lugovskoy A., Miller S., Rushe M., Sherman W., Simon K., Van Vlijmen H., et. al.
Protein Science , 2006
65.
Computational design of antibody-affinity improvement beyond in vivo maturation
Lippow S.M., Wittrup K.D., Tidor B.
Nature Biotechnology , 2007
66.
Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display
Hanes J., Schaffitzel C., Knappik A., Plückthun A.
Nature Biotechnology , 2000
67.
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
Boder E.T., Midelfort K.S., Wittrup K.D.
Proceedings of the National Academy of Sciences of the United States of America , 2000
68.
Fusion of barnase to antiferritin antibody F11 VH domain results in a partially folded functionally active protein
Shubenok D.V., Tsybovsky Y.I., Stremovskiy O.A., Deyev S.M., Martsev S.P.
Biochemistry (Moscow) , 2009
69.
Discovery of Novel Candidate Therapeutics and Diagnostics Based on Engineered Human Antibody Domains
Chen W., Gong R., Ying T., Prabakaran P., Zhu Z., Feng Y., Dimitrov D.
Current Drug Discovery Technologies , 2014
71.
The perspective of immunotherapy
Blank C.U.
Current Opinion in Oncology , 2014
74.
Fine Tuning of the Specificity of an Anti-progesterone Antibody by First and Second Sphere Residue Engineering
Dubreuil O., Bossus M., Graille M., Bilous M., Savatier A., Jolivet M., Ménez A., Stura E., Ducancel F.
Journal of Biological Chemistry , 2005
75.
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin
Garcia-Rodriguez C., Levy R., Arndt J.W., Forsyth C.M., Razai A., Lou J., Geren I., Stevens R.C., Marks J.D.
Nature Biotechnology , 2006
76.
Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.
Werther W.A., Gonzalez T.N., O'Connor S.J., McCabe S., Chan B., Hotaling T., Champe M., Fox J.A., Jardieu P.M., Berman P.W., Presta L.G.
Journal of Immunology , 1996
77.
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Bostrom J., Yu S., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., Peale F., Ross S., Wiesmann C., Fuh G.
Science , 2009
78.
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua W.F., Kiener P.A., Wu H.
Journal of Biological Chemistry , 2006
79.
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Igawa T., Ishii S., Tachibana T., Maeda A., Higuchi Y., Shimaoka S., Moriyama C., Watanabe T., Takubo R., Doi Y., Wakabayashi T., Hayasaka A., Kadono S., Miyazaki T., Haraya K., et. al.
Nature Biotechnology , 2010
80.
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
Boswell C.A., Tesar D.B., Mukhyala K., Theil F., Fielder P.J., Khawli L.A.
Bioconjugate Chemistry , 2010
81.
84
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1947
82.
Pharmacokinetics and biodistribution of genetically engineered antibodies
Batra S.K., Jain M., Wittel U.A., Chauhan S.C., Colcher D.
Current Opinion in Biotechnology , 2002
83.
Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration
Gaudreault J., Fei D., Rusit J., Suboc P., Shiu V.
Investigative Ophthalmology and Visual Science , 2005
84.
Design of multivalent complexes using the barnase·barstar module
Deyev S.M., Waibel R., Lebedenko E.N., Schubiger A.P., Plückthun A.
Nature Biotechnology , 2003
85.
Visualization of cancer cells by means of the fluorescent EGFP-barnase protein
Lebedenko E.N., Balandin T.G., Edelweiss E.F., Georgiev O., Moiseeva E.S., Petrov R.V., Deyev S.M.
Doklady Biochemistry and Biophysics , 2007
86.
89
A. A. Krasnovskii
Izd. Akad. Nauk SSSR, Moscow , 1955
87.
Antibody engineering: Molecular constructor on the basis of barnase-barstar module
Deev S.M., Lebedenko E.N.
Russian Journal of Bioorganic Chemistry , 2009
88.
91
L. M. Vorob'eva
Biokhimiya , 1956
89.
‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Ridgway J.B., Presta L.G., Carter P.
Protein Engineering, Design and Selection , 1996
90.
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting
Rossi E.A., Goldenberg D.M., Cardillo T.M., McBride W.J., Sharkey R.M., Chang C.
Proceedings of the National Academy of Sciences of the United States of America , 2006
91.
PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5
Kubetzko S., Balic E., Waibel R., Zangemeister-Wittke U., Plückthun A.
Journal of Biological Chemistry , 2006
92.
Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology
Tijink B.M., Laeremans T., Budde M., Walsum M.S., Dreier T., de Haard H.J., Leemans C.R., van Dongen G.A.
Molecular Cancer Therapeutics , 2008
93.
Perspective – FcRn transports albumin: relevance to immunology and medicine
Anderson C.L., Chaudhury C., Kim J., Bronson C.L., Wani M.A., Mohanty S.
Trends in Immunology , 2006
95.
General strategy for the generation of human antibody variable domains with increased aggregation resistance
Dudgeon K., Rouet R., Kokmeijer I., Schofield P., Stolp J., Langley D., Stock D., Christ D.
Proceedings of the National Academy of Sciences of the United States of America , 2012
97.
Structure-based Stability Engineering of the Mouse IgG1 Fab Fragment by Modifying Constant Domains
Teerinen T., Valjakka J., Rouvinen J., Takkinen K.
Journal of Molecular Biology , 2006
98.
Role of κ→λ light-chain constant-domain switch in the structure and functionality of A17 reactibody
Ponomarenko N., Chatziefthimiou S.D., Kurkova I., Mokrushina Y., Mokrushina Y., Stepanova A., Smirnov I., Avakyan M., Bobik T., Mamedov A., Mitkevich V., Belogurov A., Fedorova O.S., Dubina M., Golovin A., et. al.
Acta Crystallographica Section D Biological Crystallography , 2014
103.
FcRn-mediated antibody transport across epithelial cells revealed by electron tomography
He W., Ladinsky M.S., Huey-Tubman K.E., Jensen G.J., McIntosh J.R., Björkman P.J.
Nature , 2008
104.
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn
Lencer W.I., Blumberg R.S.
Trends in Cell Biology , 2005
105.
FcRn: the neonatal Fc receptor comes of age
Roopenian D.C., Akilesh S.
Nature Reviews Immunology , 2007
106.
Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies
Vaccaro C., Bawdon R., Wanjie S., Ober R.J., Ward E.S.
Proceedings of the National Academy of Sciences of the United States of America , 2006
107.
Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates
Hinton P.R., Johlfs M.G., Xiong J.M., Hanestad K., Ong K.C., Bullock C., Keller S., Tang M.T., Tso J.Y., Vásquez M., Tsurushita N.
Journal of Biological Chemistry , 2004
108.
Enhanced antibody half-life improves in vivo activity
Zalevsky J., Chamberlain A.K., Horton H.M., Karki S., Leung I.W., Sproule T.J., Lazar G.A., Roopenian D.C., Desjarlais J.R.
Nature Biotechnology , 2010
109.
Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions
Sockolosky J.T., Tiffany M.R., Szoka F.C.
Proceedings of the National Academy of Sciences of the United States of America , 2012
110.
High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR
Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., Presta L.G.
Journal of Biological Chemistry , 2001
111.
Engineered antibody Fc variants with enhanced effector function
Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., Vielmetter J., Carmichael D.F., Hayes R.J., Dahiyat B.I.
Proceedings of the National Academy of Sciences of the United States of America , 2006
112.
Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
Horton H.M., Bernett M.J., Pong E., Peipp M., Karki S., Chu S.Y., Richards J.O., Vostiar I., Joyce P.F., Repp R., Desjarlais J.R., Zhukovsky E.A.
Cancer Research , 2008
113.
116
V. B. Evstigneev
Dokl. Akad. Nauk SSSR , 1957
115.
Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ Receptors
Stavenhagen J.B., Gorlatov S., Tuaillon N., Rankin C.T., Li H., Burke S., Huang L., Johnson S., Bonvini E., Koenig S.
Cancer Research , 2007
117.
An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
Wilson N.S., Yang B., Yang A., Loeser S., Marsters S., Lawrence D., Li Y., Pitti R., Totpal K., Yee S., Ross S., Vernes J., Lu Y., Adams C., Offringa R., et. al.
Cancer Cell , 2011
118.
Impact of Differential Glycosylation on IgG Activity
Lux A., Nimmerjahn F.
Advances in Experimental Medicine and Biology , 2011
121.
Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIa
Iida S., Misaka H., Inoue M., Shibata M., Nakano R., Yamane-Ohnuki N., Wakitani M., Yano K., Shitara K., Satoh M.
Clinical Cancer Research , 2006
123.
Marketing approval of mogamulizumab
Beck A., Reichert J.M.
mAbs , 2012
124.
Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions
Huang W., Giddens J., Fan S., Toonstra C., Wang L.
Journal of the American Chemical Society , 2012
125.
Aglycosylated immunoglobulin G 1 variants productively engage activating Fc receptors
Sazinsky S.L., Ott R.G., Silver N.W., Tidor B., Ravetch J.V., Wittrup K.D.
Proceedings of the National Academy of Sciences of the United States of America , 2008
126.
Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system
Yin G., Garces E.D., Yang J., Zhang J., Tran C., Steiner A.R., Roos C., Bajad S., Hudak S., Penta K., Zawada J., Pollitt S., Murray C.J.
mAbs , 2012
128.
Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde
Belogurov A., Kozyr A., Ponomarenko N., Gabibov A.
BioEssays , 2009
129.
Induction of an Antibody That Catalyzes the Hydrolysis of an Amide Bond
Janda K.D., Schloeder D., Benkovic S.J., Lerner R.A.
Science , 1988
130.
Anti-Idiotypic Antibody Mimics Proteolytic Function of Parent Antigen
Ponomarenko N.A., Pillet D., Paon M., Vorobiev I.I., Smirnov I.V., Adenier H., Avalle B., Kolesnikov A.V., Kozyr A.V., Thomas D., Gabibov A.G., Friboulet A.
Biochemistry , 2007
131.
134
V. V. Korshak
Izv. Akad. Nauk SSSR, Otd. Khim. Nauk , 1948
132.
Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice
Durova O.M., Vorobiev I.I., Smirnov I.V., Reshetnyak A.V., Telegin G.B., Shamborant O.G., Orlova N.A., Genkin D.D., Bacon A., Ponomarenko N.A.
Molecular Immunology , 2009
133.
Induction of a Protein-Targeted Catalytic Response in Autoimmune Prone Mice:  Antibody-Mediated Cleavage of HIV-1 Glycoprotein GP120
Ponomarenko N.A., Vorobiev I.I., Alexandrova E.S., Reshetnyak A.V., Telegin G.B., Khaidukov S.V., Avalle B., Karavanov A., Morse H.C., Thomas D., Friboulet A., Gabibov A.G.
Biochemistry , 2005
134.
10.1002/(SICI)1521-3773(19991216)38:24<3738::AID-ANIE3738>3.0.CO;2-2
135.
Catalytic Antibodies
Smirnov I.V., Belogurov A.A., Kozyr A.V., Gabibov A.
2012
136.
Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale
Ponomarenko N.A., Durova O.M., Vorobiev I.I., Belogurov A.A., Telegin G.B., Suchkov S.V., Misikov V.K., Morse H.C., Gabibov A.G.
Immunology Letters , 2006
137.
140
1912
138.
Natural antibodies to nucleic acids
Buneva V.N., Krasnorutskii M.A., Nevinsky G.A.
Biochemistry (Moscow) , 2013
139.
Strategies for the selection of catalytic antibodies against organophosphorus nerve agents
Smirnov I., Belogurov A., Friboulet A., Masson P., Gabibov A., Renard P.
Chemico-Biological Interactions , 2013
140.
Crystallographic and Biochemical Analysis of Cocaine-Degrading Antibody 15A10,
Larsen N.A., de Prada P., Deng S.-., Mittal A., Braskett M., Zhu X., Wilson I.A., Landry D.W.
Biochemistry , 2004
142.
Idiotypic network mimicry and antibody catalysis: lessons for the elicitation of efficient anti-idiotypic protease antibodies
Pillet D., Paon M., Vorobiev I.I., Gabibov A.G., Thomas D., Friboulet A.
Journal of Immunological Methods , 2002
143.
Casein‐hydrolyzing activity of sIgA antibodies from human milk
Odintsova E.S., Buneva V.N., Nevinsky G.A.
Journal of Molecular Recognition , 2005
144.
148
P. Kresse
Chem. Abs. , 1960
146.
Catalytic antibodies to HIV: Physiological role and potential clinical utility
Planque S., Nishiyama Y., Taguchi H., Salas M., Hanson C., Paul S.
Autoimmunity Reviews , 2008
147.
CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments
Meshcheryakova D., Andreev S., Tarasova S., Sidorova M., Vafina M., Kornilaeva G., Karamov E., Khaitov R.
Molecular Immunology , 1993
148.
152
W. Albert
Trans. Electrochem. Soc. , 1943
149.
CD4 binding determinant mimicry for HIV vaccine design
Nishiyama Y., Planque S., Hanson C.V., Massey R.J., Paul S.
Frontiers in Immunology , 2012
150.
Naturally Occurring Proteolytic Antibodies
Paul S., Karle S., Planque S., Taguchi H., Salas M., Nishiyama Y., Handy B., Hunter R., Edmundson A., Hanson C.
Journal of Biological Chemistry , 2004
151.
Characterization of gp120 Hydrolysis by IgA Antibodies from Humans without HIV Infection
Planque S., Mitsuda Y., Taguchi H., Salas M., Morris M., Nishiyama Y., Kyle R., Okhuysen P., Escobar M., Hunter R., Sheppard H.W., Hanson C., Paul S.
AIDS Research and Human Retroviruses , 2007
152.
Routes to Covalent Catalysis by Reactive Selection for Nascent Protein Nucleophiles
Reshetnyak A.V., Armentano M.F., Ponomarenko N.A., Vizzuso D., Durova O.M., Ziganshin R., Serebryakova M., Govorun V., Gololobov G., Morse H.C., Friboulet A., Makker S.P., Gabibov A.G., Tramontano A.
Journal of the American Chemical Society , 2007
153.
Reactibodies generated by kinetic selection couple chemical reactivity with favorable protein dynamics
Smirnov I., Carletti E., Kurkova I., Nachon F., Nicolet Y., Mitkevich V.A., Débat H., Avalle B., Belogurov A.A., Kuznetsov N., Reshetnyak A., Masson P., Tonevitsky A.G., Ponomarenko N., Makarov A.A., et. al.
Proceedings of the National Academy of Sciences of the United States of America , 2011
154.
Heavy–light chain interrelations of MS-associated immunoglobulins probed by deep sequencing and rational variation
Lomakin Y.A., Zakharova M.Y., Stepanov A.V., Dronina M.A., Smirnov I.V., Bobik T.V., Pyrkov A.Y., Tikunova N.V., Sharanova S.N., Boitsov V.M., Vyazmin S.Y., Kabilov M.R., Tupikin A.E., Krasnov A.N., Bykova N.A., et. al.
Molecular Immunology , 2014
157.
Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
Sharkey R.M., Karacay H., Cardillo T.M., Chang C., McBride W.J., Rossi E.A., Horak I.D., Goldenberg D.M.
Clinical Cancer Research , 2005
159.
A modular design of low-background bioassays based on a high-affinity molecular pair barstar:barnase
Sreenivasan V.K., Kelf T.A., Grebenik E.A., Stremovskiy O.A., Say J.M., Rabeau J.R., Zvyagin A.V., Deyev S.M.
Proteomics , 2013
160.
In vivosite-specific biotinylation of proteins within the secretory pathway using a single vector system
Predonzani A., Arnoldi F., López-Requena A., Burrone O.R.
BMC Biotechnology , 2008
161.
Targeting quantum dots to surface proteins in living cells with biotin ligase
Howarth M., Takao K., Hayashi Y., Ting A.Y.
Proceedings of the National Academy of Sciences of the United States of America , 2005
162.
Submicron polymer particles containing fluorescent semiconductor nanocrystals CdSe/ZnS for bioassays
Generalova A.N., Sizova S.V., Zdobnova T.A., Zarifullina M.M., Artemyev M.V., Baranov A.V., Oleinikov V.A., Zubov V.P., Deyev S.M.
Nanomedicine , 2011
163.
Fluorescent immunolabeling of cancer cells by quantum dots and antibody scFv fragment
Zdobnova T.A., Dorofeev S.G., Tananaev P.N., Vasiliev R.B., Balandin T.G., Edelweiss E.F., Stremovskiy O.A., Balalaeva I.V., Turchin I.V., Lebedenko E.N., Zlomanov V.P., Deyev S.M.
Journal of Biomedical Optics , 2009
164.
Zdobnova T.A., Lebedenko E.N., Deyev S.M.
Acta Naturae , 2011
167.
Feasibility study of the optical imaging of a breast cancer lesion labeled with upconversion nanoparticle biocomplexes
Grebenik E.A., Nadort A., Generalova A.N., Nechaev A.V., Sreenivasan V.K., Khaydukov E.V., Semchishen V.A., Popov A.P., Sokolov V.I., Akhmanov A.S., Zubov V.P., Klinov D.V., Panchenko V.Y., Deyev S.M., Zvyagin A.V., et. al.
Journal of Biomedical Optics , 2013
168.
Protein-assisted self-assembly of multifunctional nanoparticles
Nikitin M.P., Zdobnova T.A., Lukash S.V., Stremovskiy O.A., Deyev S.M.
Proceedings of the National Academy of Sciences of the United States of America , 2010
170.
Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results
Schoffelen R., Boerman O.C., Goldenberg D.M., Sharkey R.M., van Herpen C.M., Franssen G.M., McBride W.J., Chang C., Rossi E.A., van der Graaf W.T., Oyen W.J.
British Journal of Cancer , 2013
171.
Immunotoxin Treatment of Cancer
Pastan I., Hassan R., FitzGerald D.J., Kreitman R.J.
Annual Review of Medicine , 2007
172.
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes
Onda M., Beers R., Xiang L., Lee B., Weldon J.E., Kreitman R.J., Pastan I.
Proceedings of the National Academy of Sciences of the United States of America , 2011
173.
Barnase as a New Therapeutic Agent Triggering Apoptosis in Human Cancer Cells
Edelweiss E., Balandin T.G., Ivanova J.L., Lutsenko G.V., Leonova O.G., Popenko V.I., Sapozhnikov A.M., Deyev S.M.
PLoS ONE , 2008
175.
Design of Targeted B Cell Killing Agents
Stepanov A.V., Belogurov A.A., Ponomarenko N.A., Stremovskiy O.A., Kozlov L.V., Bichucher A.M., Dmitriev S.E., Smirnov I.V., Shamborant O.G., Balabashin D.S., Sashchenko L.P., Tonevitsky A.G., Friboulet A., Gabibov A.G., Deyev S.M., et. al.
PLoS ONE , 2011
176.
Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts
Balandin T.G., Edelweiss E., Andronova N.V., Treshalina E.M., Sapozhnikov A.M., Deyev S.M.
Investigational New Drugs , 2009
177.
From ImmunoToxins to ImmunoRNases
Lorenzo C., D'Alessio G.
Current Pharmaceutical Biotechnology , 2008
178.
Targeting: The ADEPT Story So Far
Bagshawe K.
Current Drug Targets , 2009
179.
Intratumoral immunocytokine treatment results in enhanced antitumor effects
Johnson E.E., Lum H.D., Rakhmilevich A.L., Schmidt B.E., Furlong M., Buhtoiarov I.N., Hank J.A., Raubitschek A., Colcher D., Reisfeld R.A., Gillies S.D., Sondel P.M.
Cancer Immunology, Immunotherapy , 2008
180.
The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer
Wagner K., Schulz P., Scholz A., Wiedenmann B., Menrad A.
Clinical Cancer Research , 2008
181.
Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy
Singh H., Serrano L.M., Pfeiffer T., Olivares S., McNamara G., Smith D.D., Al-Kadhimi Z., Forman S.J., Gillies S.D., Jensen M.C., Colcher D., Raubitschek A., Cooper L.J.
Cancer Research , 2007
183.
Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein
Serebrovskaya E.O., Edelweiss E.F., Stremovskiy O.A., Lukyanov K.A., Chudakov D.M., Deyev S.M.
Proceedings of the National Academy of Sciences of the United States of America , 2009
184.
Mironova K.E., Proshkina G.M., Ryabova A.V., Stremovskiy O.A., Lukyanov S.A., Petrov R.V., Deyev S.M.
Theranostics , 2013
185.
A genetically encoded photosensitizer
Bulina M.E., Chudakov D.M., Britanova O.V., Yanushevich Y.G., Staroverov D.B., Chepurnykh T.V., Merzlyak E.M., Shkrob M.A., Lukyanov S., Lukyanov K.A.
Nature Biotechnology , 2005
186.
A Genetically Encoded Tag for Correlated Light and Electron Microscopy of Intact Cells, Tissues, and Organisms
Shu X., Lev-Ram V., Deerinck T.J., Qi Y., Ramko E.B., Davidson M.W., Jin Y., Ellisman M.H., Tsien R.Y.
PLoS Biology , 2011
187.
Epithelial Junction Opener JO-1 Improves Monoclonal Antibody Therapy of Cancer
Beyer I., van Rensburg R., Strauss R., Li Z., Wang H., Persson J., Yumul R., Feng Q., Song H., Bartek J., Fender P., Lieber A.
Cancer Research , 2011
189.
193
E. Pannain
Gazzetta , 1909
190.
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
Robinson M.K., Hodge K.M., Horak E., Sundberg Å.L., Russeva M., Shaller C.C., von Mehren M., Shchaveleva I., Simmons H.H., Marks J.D., Adams G.P.
British Journal of Cancer , 2008
191.
195
M. Allen
J. Chem. Soc. , 1961
193.
Antibody Targeting of Stem Cells to Infarcted Myocardium
Lee R.J., Fang Q., Davol P.A., Gu Y., Sievers R.E., Grabert R.C., Gall J.M., Tsang E., Yee M.S., Fok H., Huang N.F., Padbury J.F., Larrick J.W., Lum L.G.
Stem Cells , 2006
194.
An efficient chemical approach to bispecific antibodies and antibodies of high valency
Gavrilyuk J.I., Wuellner U., Salahuddin S., Goswami R.K., Sinha S.C., Barbas C.F.
Bioorganic and Medicinal Chemistry Letters , 2009
195.
Expression of single-chain antibody-barstar fusion in plants
Semenyuk E.G., Stremovskiy O.A., Edelweiss E.F., Shirshikova O.V., Balandin T.G., Buryanov Y.I., Deyev S.M.
Biochimie , 2007
196.
A revival of bispecific antibodies
Kufer P., Lutterbüse R., Baeuerle P.A.
Trends in Biotechnology , 2004
197.
Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma
Marmé A., Strauß G., Bastert G., Grischke E., Moldenhauer G.
International Journal of Cancer , 2002
198.
Enhanced Killing of Primary Ovarian Cancer by Retargeting Autologous Cytokine-Induced Killer Cells with Bispecific Antibodies: A Preclinical Study
Chan J.K., Hamilton C.A., Cheung M.K., Karimi M., Baker J., Gall J.M., Schulz S., Thorne S.H., Teng N.N., Contag C.H., Lum L.G., Negrin R.S.
Clinical Cancer Research , 2006
199.
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., Noppeney R., Viardot A., Hess G., Schuler M., Einsele H., Brandl C., Wolf A., Kirchinger P., Klappers P., et. al.
Science , 2008
200.
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Sierra J.R., Cepero V., Giordano S.
Molecular Cancer , 2010
201.
Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody
Lu D., Zhang H., Ludwig D., Persaud A., Jimenez X., Burtrum D., Balderes P., Liu M., Bohlen P., Witte L., Zhu Z.
Journal of Biological Chemistry , 2004
202.
Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides
LaFleur D., Abramyan D., Kanakaraj P., Smith R., Shah R., Wang G., Yao X., Kankanala S., Boyd E., Zaritskaya L., Nam V., Puffer B., Buasen P., Kaithamana S., Burnette A., et. al.
mAbs , 2013
203.
Engineering novel binding proteins from nonimmunoglobulin domains
Binz H.K., Amstutz P., Plückthun A.
Nature Biotechnology , 2005
204.
Alternative scaffold proteins
Petrovskaya L.E., Shingarova L.N., Dolgikh D.A., Kirpichnikov M.P.
Russian Journal of Bioorganic Chemistry , 2011
205.
209
C. J. Haggerty
Trans. Am. Electrochem. Soc. , 1929
206.
Affinity proteins and their generation
Ståhl S., Kronqvist N., Jonsson A., Löfblom J.
Journal of Chemical Technology and Biotechnology , 2012
207.
Engineered affinity proteins—Generation and applications
Grönwall C., Ståhl S.
Journal of Biotechnology , 2009
208.
Replacing Antibodies: Engineering New Binding Proteins
Banta S., Dooley K., Shur O.
Annual Review of Biomedical Engineering , 2013
209.
DARPins and other repeat protein scaffolds: advances in engineering and applications
Boersma Y.L., Plückthun A.
Current Opinion in Biotechnology , 2011
210.
High-affinity single-domain binding proteins with a binary-code interface
Koide A., Gilbreth R.N., Esaki K., Tereshko V., Koide S.
Proceedings of the National Academy of Sciences of the United States of America , 2007
214.
Binding proteins from alternative scaffolds.
Nygren P., Skerra A.
Journal of Immunological Methods , 2004
215.
Adnectins: engineered target-binding protein therapeutics
Lipovsek D.
Protein Engineering, Design and Selection , 2010
216.
Engineering Fibronectin-Based Binding Proteins by Yeast Surface Display
Chen T.F., de Picciotto S., Hackel B.J., Wittrup K.D.
Methods in Enzymology , 2013
217.
Epitope-Guided Engineering of Monobody Binders for in Vivo Inhibition of Erk-2 Signaling
Mann J.K., Wood J.F., Stephan A.F., Tzanakakis E.S., Ferkey D.M., Park S.
ACS Chemical Biology , 2012
218.
Construction of TNF-binding proteins by grafting hypervariable regions of F10 antibody on human fibronectin domain scaffold
Petrovskaya L.E., Shingarova L.N., Kryukova E.A., Boldyreva E.F., Yakimov S.A., Guryanova S.V., Novoseletsky V.N., Dolgikh D.A., Kirpichnikov M.P.
Biochemistry (Moscow) , 2012
219.
A Novel Fusion Toxin Derived from an EpCAM-Specific Designed Ankyrin Repeat Protein Has Potent Antitumor Activity
Martin-Killias P., Stefan N., Rothschild S., Plückthun A., Zangemeister-Wittke U.
Clinical Cancer Research , 2011
220.
DARPins as Bispecific Receptor Antagonists Analyzed for Immunoglobulin E Receptor Blockage
Eggel A., Baumann M.J., Amstutz P., Stadler B.M., Vogel M.
Journal of Molecular Biology , 2009
221.
Epidermal growth factor receptor downregulation by small heterodimeric binding proteins.
Hackel B.J., Neil J.R., White F.M., Wittrup K.D.
Protein Engineering, Design and Selection , 2011
224.
Affibody-β-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol
Rönnmark J., Kampf C., Asplund A., Höidén-Guthenberg I., Wester K., Pontén F., Uhlén M., Nygren P.
Journal of Immunological Methods , 2003
225.
Alternative non-antibody protein scaffolds for molecular imaging of cancer
Stern L.A., Case B.A., Hackel B.J.
Current Opinion in Chemical Engineering , 2013
226.
PET Imaging of Tumor Neovascularization in a Transgenic Mouse Model with a Novel 64Cu-DOTA-Knottin Peptide
Nielsen C.H., Kimura R.H., Withofs N., Tran P.T., Miao Z., Cochran J.R., Cheng Z., Felsher D., Kjær A., Willmann J.K., Gambhir S.S.
Cancer Research , 2010
227.
Fluorescent fusion proteins derived from the tenth human fibronectin domain
Petrovskaya L.E., Gapizov S.S., Shingarova L.N., Kryukova E.A., Boldyreva E.F., Yakimov S.A., Svirschevskaya E.V., Lukashev E.P., Dolgikh D.A., Kirpichnikov M.P.
Russian Journal of Bioorganic Chemistry , 2014
228.
Passive and active targeting of quantum dots for whole-body fluorescence imaging of breast cancer xenografts
Balalaeva I.V., Zdobnova T.A., Krutova I.V., Brilkina A.A., Lebedenko E.N., Deyev S.M.
Journal of Biophotonics , 2012
229.
G-DOC: A Systems Medicine Platform for Personalized Oncology
Madhavan S., Gusev Y., Harris M., Tanenbaum D.M., Gauba R., Bhuvaneshwar K., Shinohara A., Rosso K., Carabet L.A., Song L., Riggins R.B., Dakshanamurthy S., Wang Y., Byers S.W., Clarke R., et. al.
Neoplasia , 2011